Abstract:Abstract The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) —a homologue of ACE—to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin–angiotensin–aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.

Cardiovascular Complications in Coronavirus Disease 2019—Pathogenesis and Management

Effects of COVID-19 on Arrhythmia

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Trusting the Record

Covid-19 and the cardiovascular system: a comprehensive review

Coronavirus disease 2019 and cardiovascular complications: focused clinical review

Cardiovascular aspects of COVID-19

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

[The heart remembers...and if we remember that, unnecessary examinations can be avoided].

COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19

Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment

COVID-19 and cardiovascular complications: updates of emergency medicine

COVID-19 and the cardiovascular system: a study of pathophysiology and interpopulation variability

The effects of water-soluble solutes on the phase transitions of phospholipids.

Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response

Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality

A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease

Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)

SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management

Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic